1. Norcantharidin(NCTD) has been used to treat human cancers in China since 1984.
2. Norcantharidin, a protein phosphatase type-2A inhibitor, which has less nephrotoxic and phlogogenic side-effects, it can inhibit both DNA synthesis and granulocyte-macrophage colony-forming cells (GM-CFC)growth and impaire the neogenesis of chromatin material and nuclear membrane during the M/G1 phase transition in K-562 cells.
3. Norcantharidin inhibits the canonical Wnt signal pathway in NSCLC, by activating WIF-1 via promoter demethylation.
4. Norcantharidin could be an effective agent for targeting neo-lymphangiogenesis to inhibit lymphangiogenesis, by downregulating the expression of VEGF-C and VEGF-D.
5. Norcantharidin enhances TIMP‑2 antitumor and anti‑VM activities in GBCs through downregulating MMP‑2 and MT1‑MMP.